Abstract |
Hybrid fusion genes are specific tumor markers of several leukemic subtypes. The use of reverse transcription-polymerase chain reaction (RT-PCR) to amplify chimeric cDNAs allows sensitive detection of the leukemia clone. The clinical relevance of minimal residual disease (MRD) remains controversial. In this report, an infantile acute lymphoblastic leukemia with t(4;11) (q21; q23) was analyzed after each treatment for the presence of MRD by RT-PCR amplification of the MLL/ LTG4 fusion gene which became available recently. The patient soon achieved a hematological CR, after induction therapy, and underwent autologous BMT following consolidation chemotherapy for 9 months. However, he relapsed three months after the BMT. MRD was always detectable during his clinical course. These findings suggest that the detection of MRD of the MLL/ LTG4 fusion transcript is a useful tool for monitoring MRD and selecting treatment.
|
Authors | T Okamura, Y D Park, M Inoue, M Yasui, M Ueno, C Endo, K Yagi, K Kawa |
Journal | [Rinsho ketsueki] The Japanese journal of clinical hematology
(Rinsho Ketsueki)
Vol. 37
Issue 11
Pg. 1318-21
(Nov 1996)
ISSN: 0485-1439 [Print] Japan |
PMID | 8960669
(Publication Type: Case Reports, English Abstract, Journal Article, Research Support, Non-U.S. Gov't)
|
Topics |
- Child, Preschool
- Chromosomes, Human, Pair 11
- Chromosomes, Human, Pair 4
- Humans
- Male
- Neoplasm, Residual
- Polymerase Chain Reaction
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(genetics)
- Translocation, Genetic
|